A hospital ward has its own particular sound, a hum of monitors and quiet footsteps and the low murmur of families trying to hold themselves together. It was in that sound, over ten years at academic hospitals including The Royal Marsden, that a young physician first understood what she wanted her working life to be about. She was treating adults and children with complex, life-limiting conditions, many of them living with rare diseases that had no easy answers. “Nothing really prepares you for sitting with those families,” she says now, “but knowing you helped in some way was still rewarding.”
That physician is Dr. Verity Rawson, and two decades later she is the Executive Medical Director and Founder of Omvita Medical, a consultancy built to solve one of the pharmaceutical industry’s most stubborn problems: helping promising medicines transition from successful clinical development to real-world patient access.
A Curiosity That Never Left the Room
Dr. Rawson did not arrive at global medical affairs by a straight line. She trained as a physician, she says, because she carried a humanitarian leaning alongside an intense curiosity of human biology, and both instincts pulled her toward medicine’s harder edges rather than its more predictable corners. Her ten years on the wards were not a prelude to something else. They were the foundation. The clinical grounding she absorbed at the bedside, and the executive appetite she later developed for building systems that could reach far more patients than one doctor ever could alone, are the same thread running through everything she has done since.
That thread led her into industry, where she spent thirteen years as a medical advisor and leader, learning the machinery of drug development from the inside before deciding to build something of her own.
The Founding of Omvita Medical
Omvita Medical exists because of a very specific gap that Dr. Rawson kept encountering. Brilliant, science-driven biotech organizations would reach a pivotal moment, somewhere around Phase 2 or 3 and before commercial launch, and find themselves with the need for medical leadership to prepare for the successful adoption into the clinical arena ahead. She calls it a structural challenge as much as a scientific one. Lean biotechs developing genuinely novel modalities, cell and gene therapies among them, and the utilization of emerging tools like AI-enabled study design and LLM testing, simply did not have the bridge they needed between ambition and execution.
Building that bridge became her mission. Omvita’s vision, as she describes it, was to translate scientific ambition into an executable global clinical development and medical affairs strategy, offering tangible medical input, commercial direction, and boardroom-level planning for the rare disease innovators who need it most. Across her career, she has helped launch nine products and has managed more than one hundred others.
The Problem Beneath the Problem
Ask Dr. Rawson what troubles her most about rare disease, immuno-oncology, and complex medicine access today, and she does not point just to the safety of the science itself. She points to everything that happens around it.
Small, heterogeneous patient populations make conventional trial design difficult from the start. Novel mechanisms of action can challenge the traditional regulatory frameworks meant to evaluate them. And even when a medicine clears every scientific hurdle and wins approval, it often runs into reimbursement and access systems that were never built with orphan economics in mind. These systems, she notes, were designed for common diseases, not rare ones.
She finds none of this discouraging. If anything, she describes it as “genuinely energizing rather than daunting,” the exact place where curious, pioneering, and collaborative medical leadership can make a real difference.
A Method Built on Both Sides of the Table
Dr. Rawson’s approach to Clinical Development blends clinical instinct with methodological tactics. She has used OMICs-driven biomarker discovery and digital twin modeling to help shape and sharpen study designs in rare disease programs, at a moment when regulators themselves are pushing for more innovative, more continuously accurate data. Basket trials and natural history studies, she explains, have shown they can answer the same scientific question across a broader range of patients with unmet needs.
What she believes sets her leadership apart in Medical Affairs is something less technical and more personal: she has sat on both sides of the doctor’s table. She can speak coherently to a regulator, to a key opinion leader, and to the impassioned director of a patient organization, often within the same week. She tries to lead teams with the same warmth and clarity she would want at a patient’s bedside, keeping her irreverent humour intact along the way.
Where Launch, Regulation, and Access Meet
None of this work matters in isolation, Dr. Rawson is quick to point out. Launch execution, regulatory strategy, and global access programs only matter when they function as a large, coordinated team effort. A brilliant medicine that cannot secure orphan designation, pediatric labeling, or expanded access, she says plainly, is a brilliant medicine nobody can use.
Across her career, she has supported the strategic groundwork behind numerous product launches, including two that became global blockbusters, while helping secure orphan designations and expanded access across the FDA, EMA, and PMDA. Each of these pieces, done well and done in concert, closes the distance between the researchers who commit to early drug development and the patient who eventually benefits from it.
The Shape of an Ordinary Day
Day to day, Dr. Rawson describes her role as equal parts strategist, translator, and builder. She advises C-level teams on Clinical Development planning and Medical Affairs launch excellence strategy, designs integrated evidence generation plans, builds company medical affairs functions from the ground up, and mentors the next generation of medical leaders coming up behind her.
What still moves her, twenty years into this work, is the specific moment when a scientific justification turns into a regulatory or access decision with the power to change a patient’s life. That, she says, remains the best part of the job. That moment is never achieved by one person alone, which naturally brings her to the teams behind every success.
The People Behind the Strategy
Dr. Rawson is emphatic that none of this happens alone. She has led extraordinary teams across pharmacovigilance and medical information, and worked closely with teams from biometrics and CMC functions. During COVID, she helped coordinate twelve Chief Medical Officers on deliverables around a single global strategy. Patient advocacy organizations, she says, have kept everyone clear about what actually matters throughout.
Her collaborations have carried her further afield than most medical careers reach. She has presented scientific data to the Emirati Ministry of Health, negotiated government funding inclusions, and built expert networks that span continents. “Collaboration is not a competency on a CV,” she says. “It is the mechanism by which medicines reach people.”
The Setback That Would Not Be the Final Word
Every career in this field eventually meets its hardest test, and for Dr. Rawson, it arrived in the form of a rejected regulatory decision on a drug she believed in, something many medical directors face. The easy response to a regulatory no, she says, is either to accept it or to get defensive. Her team chose neither. Instead, they rebuilt the scientific argument from the ground up, addressed the perceived gaps using real-world data, re-engaged the disease community, and made the case again with more rigor, smarter evidence generation, humility, and patience.
It worked. And the experience taught her something she still carries: that confidence in leadership has less to do with certainty, and more to do with refusing to let a setback be the final word when patients are waiting.
The Milestones She Points to With Pride
Ask Dr. Rawson what she is proudest of, and the answer is concrete rather than sentimental. She points to contributing to the launch of two blockbuster drugs, one in respiratory medicine and one in oncology, watching both become transformative therapies worldwide. She points to strategizing global RNA diagnostic platforms across twelve countries, work that delivered 250 percent above forecast ROI, and to growing a medical team from fifty people to eighty-six high-functioning individuals with a shared purpose.
And beneath all of it, she points to something less measurable: understanding, deeply, what families face when they have little to no treatment options available. That understanding, she says, is what continues to drive her.
Looking at What Comes Next
Dr. Rawson’s vision for the future rests on the belief that AI-enabled clinical development, from OMICs biomarker discovery to digital study arms, safety planning, smarter study design, and enhancing registry data, will keep compressing the time between a hypothesis and its answer. This, alongside close working with patient advocacy groups and supporting regulators in new methodology robustness matters most, she says, in rare disease, where small patient numbers have always been the limiting factor.
Her hope is not just that the science accelerates. It is that global medicine access evolves just as quickly, ensuring innovation reaches the people who need it.
What Balance Actually Looks Like
For someone whose working life is built around global time zones and regulatory deadlines, Dr. Rawson’s idea of balance is refreshingly specific. It is not about even division of hours, she explains, but about protecting a few things fiercely.
Outside of medicine, she is an unapologetically enthusiastic hiker, a keen home cook, and a painter who recently, by her own account, got bitten by the pickleball bug. She also holds a diploma in coaching, which she has used to privately coach professional peers, an experience she says has taught her as much about herself as about the people she coaches. Mostly, though, she credits balance to genuinely enjoying the work, understanding her own energy needs, and maintaining clear boundaries to protect her well-being.
A Closing Philosophy
For Dr. Rawson, the defining quality of exceptional medical leadership is the ability to balance rigor with warmth. The best medical leadership strategy she has encountered, and the kind she tries to practice herself, holds exacting scientific standards in one hand and human consideration in the other. She is quick to add that she is still learning how to perfect this.
Her closing message is simple, and it is the same one that has guided her for twenty years: stay curious, back your teams properly, and remember that behind every study and every regulatory filing is a patient who has already been waiting long enough.
Quotes
